Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:22:55.259Z.
Calculation as of: 2026-10-06T16:22:55.259Z.
Quote observation: 2026-10-06T16:20:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$534.64M
EV/Sales Ratio
566.38x
TTM Avg
273.93x
3Y Avg
336.09x
5Y Avg
336.09x
Market Cap
$539.58M
EV/Sales Ratio
5.18x
TTM Avg
4.75x
3Y Avg
15.43x
5Y Avg
15.84x
Market Cap
$540.01M
EV/Sales Ratio
2.19x
TTM Avg
5.65x
3Y Avg
62.35x
5Y Avg
62.35x
Market Cap
$520.39M
EV/Sales Ratio
29.47x
TTM Avg
23.82x
3Y Avg
1214.34x
5Y Avg
954.66x
Market Cap
$519.25M
EV/Sales Ratio
15869.08x
TTM Avg
12786.98x
3Y Avg
8694.17x
5Y Avg
5938.95x
Market Cap
$548.84M
EV/Sales Ratio
64.44x
TTM Avg
53.58x
3Y Avg
21.24x
5Y Avg
46.54x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $528.79M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $534.64M | 566.38x | 273.93x | 336.09x | 336.09x |
| Delcath Systems, Inc. (DCTH)vs › | $539.58M | 5.18x | 4.75x | 15.43x | 15.84x |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.01M | 2.19x | 5.65x | 62.35x | 62.35x |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.68M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $520.39M | 29.47x | 23.82x | 1214.34x | 954.66x |
| Altimmune, Inc. (ALT)vs › | $519.25M | 15869.08x | 12786.98x | 8694.17x | 5938.95x |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $548.84M | 64.44x | 53.58x | 21.24x | 46.54x |
| Nuvectis Pharma, Inc. (NVCT)vs › | $546.52M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $548.18M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
